We are pleased that after the long COVID lockdown we were able to visit the south African sites to touch base and to discuss the conduct of the trial and potential improvements. We thanks all centres for their warm welcome and their hospitality during our stay and hope that, once everything is more or less back to normal, we'll meet more often in person again.
Milestone achieved: 50% recruitment for a large African trial against tuberculosis in neonates completed
We are pleased to announce that a major milestone in the pivotal phase III trial (trial name: priMe) of the novel tuberculosis vaccine VPM1002 has been achieved with the recruitment of 50 % of all participants. Read more!
The priMe organizational team (VPM, SIIPL, DiagnoSearch, IAVI) met last week at SIIPL in Pune, India to discuss the status of the project and how to streamline certain procedures to achieve the milestones and bring the trial to success.
Did you know that the 100-year-old BCG is the only vaccine available to protect against TB, and the world urgently needs a better TB vaccine?
There are several vaccine candidates in the pipeline, and our VPM1002 is one of the most advanced ones. The Scientist reported about the latest updates in the TB vaccine development. Click here to read the full article.
We are pleased to announce that all clinical trial centers, located in Kenya, Tanzania, Uganda, South Africa and Gabon, have started their recruitment and are actively enrolling participants into the pivotal phase III trial (priMe) of the novel tuberculosis vaccine VPM1002.
We thank all consortium partners for the effort in achieving this milestone!
Memo Therapeutics AG Antibodies Against SARS-CoV-2 Show Efficacy Against British and South African Variant
Vakzine Projekt Management supports Memo Therapeutics AG in the clinical development of MTX-COVAB, human-derived antibody against SARS-CoV-2 which has shown excellent neutralizing efficacy against both the original virus as well as the UK variant. Read more!
COVIVAXX is a new vaccine candidate to protect against COVID-19. Developed by the Serum Institute of India Pvt. LTD (SIIPL), the globally leading vaccine manufacturer, VPM coordinates the clinical development in Europe. A phase I/II trial is currently ongoing in Australia to assess the safety and immunogenicity of COVIVAXX in humans. A pivotal phase III trial is planned to be conducted in Europe and India in the first half of 2021. Click here to read more.
Milestone achieved: Initiation of all clinical centers for a large African trial against tuberculosis in neonates completed
We are pleased to announce that a major milestone in the pivotal phase III trial (trial name: priMe) of the novel tuberculosis vaccine VPM1002 has been achieved with the completed initiation of all clinical trial centers. Read more!